A new episode of our podcast, Two Scientists Walk Into A Bar just dropped! Antibody engineers Yan Wu and Paul Carter join us to discuss all things antibodies – from initial obstacles in developing antibody therapies, to advances in antibody engineering that are creating new classes of medicines. Plus, they share their thoughts on how #ArtificialIntelligence and #MachineLearning will be game changers for optimizing antibody design and generating new therapeutic antibodies from scratch. Listen to the full episode here: http://spr.ly/6047gmjD9
Genentech’s Post
More Relevant Posts
-
💊Exciting News! 💊 From June 20-21, Lionel Renaud, Senior Modeler at LYO-X, will be attending the 12th Antibody Industrial Symposium (AIS2024) in picturesque Montpellier, France! This prestigious conference brings together experts in therapeutic antibodies, recombinant proteins, and cellular immunotherapy to share the latest in research, development, and clinical advancements. We're thrilled to announce that Lionel, invited by Pierre Ferre, SVP of Preclinical Development & Corporate Operations at Compugen, will be delivering an insightful talk. He will discuss how PK/PD modeling can be a game-changer in overcoming challenges and avoiding pitfalls in therapeutic antibody development. In his presentation, Lionel will delve into: 🎯 Tackling reduced antibody exposure due to target-mediated drug disposition (TMDD) 📊 Understanding factors influencing effect duration (target turnover, antibody-target binding affinity) ⛵ Navigating target cross-reactivity 😷 Addressing antibody immunogenicity in preclinical species Don't miss this opportunity to gain valuable insights from Lionel's expertise. Date: 21 June 2024 Time: 08:30hrs Venue: CORUM Conference Centre, Montpellier (F), Einstein Auditorium Stay tuned for updates from AIS2024! #AIS2024 #AntibodyTherapeutics #PKPDModeling #LYOX #Compugen #TherapeuticAntibodies #Immunotherapy #BiotechInnovation
To view or add a comment, sign in
-
In this episode of cc: Life Science, recorded at #BIO2024 in San Diego, I had the pleasure of speaking with Martin Brenner, the CEO and CSO of iBio. Our focus was the challenges and innovations in developing antibody-based therapeutics, particularly through their epitope engineering platform. Martin shared his insights into the current landscape and future directions of antibody therapies, touching on key aspects such as target selection, engineering challenges, and the role of AI in optimizing therapeutic antibodies. Antibodies have revolutionized therapeutic approaches over the past two decades, with numerous successful drugs already approved. However, as Martin pointed out, we've now picked much of the low-hanging fruit. The target space is becoming increasingly complex, with most approved antibodies focusing on a small set of targets. For instance, about 40% of all approved antibodies target PD-1. While anyone can now develop a PD-1 antibody, the real challenge lies in identifying and effectively targeting novel, more complex antigens. Another significant challenge Martin highlighted is improving the safety and therapeutic window of antibodies. Highly potent antibodies, particularly in oncology, can cause severe side effects. Enhancing the safety profile while maintaining efficacy is a critical area of ongoing research. Surprisingly, it turns out that the best-binding antibody isn't always the most effective therapeutic. I find iBio's approach particularly interesting both in terms of finding better candidates and uncovering new biology in the process. Listen to the full episode to learn more and please subscribe to my Substack if you find this content valuable. https://lnkd.in/egaCjqgs #biotechnology #lifesciences #antibodytherapeutics #storytelling #healthcare 👋 Hi, I’m Chris 🎙️ Founder and host of Life Science Marketing Radio. 👉🏻 Your deepest insights are your best branding. 💌Learn more at https://lnkd.in/eDj2XGSy
To view or add a comment, sign in
-
Are 'smart' antibodies redefining how we tackle disease...? The recording of our discussion with Tzvika Hartman from Biolojic Design, Ltd. is the perfect opportunity to find out how! Take a break from the endless articles and tune in! 🎧 🎙️FODD Series 10 - Reimagining Therapeutic Antibodies Using AI Listen here! 🔗 https://hubs.la/Q021KxCR0 Learn how Biolojic's technology is being used to pioneer new antibody therapeutics in #autoimmunity and #immunooncology! #FODD #drugdiscovery #machinelearning
To view or add a comment, sign in
-
The ongoing debate between in vivo and in vitro sources and strategies for antibody discovery and generation remains a hot topic among antibody research groups. 🧬 In Vitro Approaches: - Advocates highlight the technical advancements of current in vitro technologies. - Emphasize the moral obligation to reduce animal usage in research. 🐾 In Vivo Approaches: - Supporters argue for the superior performance of animal-derived antibodies. - Highlight better affinity, specificity, and reduced immunogenicity risk. 💡 Both sides present valid points, making the decision on which strategy to implement dependent on the specific type of antibody and the technologies used for their discovery and generation. 📖 Explore our comprehensive article on antibody discovery technologies, comparing in vivo and in vitro methods, and see how polyclonal antibody sequencing fits into the mix. Read it here: https://hubs.li/Q02H4G2j0 #AntibodyDiscovery #AntibodyDevelopment #AntibodySequencing #ProteinSequencing
To view or add a comment, sign in
-
Assistant Managing Editor at Scientific Research and Community ltd | Open Access Publishers | Social Media Promoter |
📜 Research Article: ✍🏻Ashwani Mathur #Development of #Optimized #Strategy for #Cloning, #Expression and Analysis of a #Recombinant #Anti-CD20 #Therapeutic #Monoclonal #Antibody in #HEK-293 #Cells #Introduction Monospecific antibodies, also known as monoclonal antibodies (mAb), may bind to a specific epitope. The B cells that produce these antibodies are homogeneous hybrids.... #Materials and #Methods Selection of #Gene #Sequence The Heavy and light chain amino acid and nucleotide sequence of rituximab obtained from literature source viz. patent etc is aligned with the sequence obtained from Drug bank and other sources using BLAST..... #Discussions This work used stringent procedures to create and purify a recombinant monoclonal antibody (mAb) that targets CD20. CD20 is a therapeutic target since it is located on the surface of some cancer cells. Rituximab is a chimeric monoclonal antibody that targets CD20.... #Conclusion This study successfully designed and produced a recombinant anti-CD20 monoclonal antibody using a mammalian HEK-293 cell expression system.... 📰 Get full-length article here: https://lnkd.in/gtvhQWuA We do accept #PPTs and #Video Articles to be publish within our Journal. You can send us your article to given email #Email: [email protected]
To view or add a comment, sign in
-
As a result of the pandemic, everyone is now familiar with mRNA vaccines and their advantages over traditional inactivated vaccines. What other opportunities does mRNA biotech present to the scientific community? Rajat Suri and I recently spoke with Hannu Rajaniemi, Founder and CEO of HELIX NANOTECHNOLOGIES LTD, on the Curiosity Podcast. Hannu shares the potential of mRNA as a platform for various applications, including lab-grown meat, cancer treatment, and customized vaccines. Hannu’s broad thinking and ability to tie biotech to social impact make for an engaging conversation that highlights the exciting potential of mRNA technology. Listen to the full episode with the links in the comments below! #BioTech #mRNA #Medical #Vaccine #NanoTech #CancerResearch
To view or add a comment, sign in
-
📍 5 FREE Webcasts: Antibody Engineering & Therapeutics Digital Week taking place September 27-28, 2023 | Join hundreds of your antibody peers 📝 Find out more & book here: https://lnkd.in/eU5huWH8 The Antibody Engineering & Therapeutics Digital Week is taking place next week on 27-28 September. Time is running out to secure your free spot. During the webinar series, you’ll get cutting-edge updates on accelerated antibody discovery, novel characterisation techniques, in silico solutions, case studies and lessons learned from several antibody projects and more! Tune into 5 free-to-attend webcasts led by industry leaders from Telesis Bio, Rigaku, Benchling, Sutro Biopharma, Inc. and the University of Oslo. Join over 300 of your antibody industry peers and discover new ideas and technology applications to help you accelerate your antibody R&D programs. Even if you're unable to attend the live sessions, you'll have access to the recordings afterward. This exclusive content is brought to you by the organizers of the renowned Antibody Engineering & Therapeutics Europe (Amsterdam) and US (San Diego) events. Don't miss out on this exceptional opportunity. Register today to secure your place for next week's webinar series. #AntibodyEngineering #Therapeutics #Antibodies #AET #AntibodyEngDW #AntibodyTechnology #AntibodyDiscovery #AntibodyDesign
To view or add a comment, sign in
-
Ranomics One-Pot Antibody Engineering Platform in Affinity Maturation, Epitope Mapping, and Beyond... 👉 Generating and screening high diversity libraries of mutant antibodies, seamlessly integrating yeast/mammalian cell display and NGS in a single, efficient workflow. 👉Opening doors to a multitude of applications in antibody engineering and discovery - 🔍 Antibody Affinity Maturation, Epitope Mapping, Functional Antibody Screening, Disease Biomarker Discovery, Immunotherapy Development, Vaccine Development, Diagnostic Assay Optimization, Structural Biology Studies and Therapeutic Antibody Optimization 🔬 Screen full IgG or fragments scFv, Fab, VHH, BITE, Diabody.... expanding the possibilities for tailoring antibodies to specific needs. ✅ Efficiency: Our integrated approach streamlines the discovery process, saving time and resources in generating and screening diverse antibody libraries. ✅ Accuracy: Next-generation sequencing provides a comprehensive view of genetic diversity, enabling more informed decisions in candidate selection. ✅ Cost-Effectiveness: The One-Pot system reduces overall costs by consolidating multiple steps into a single platform, making it an attractive option for research and development teams. ✅ Diversity: We're committed to genetic diversity, ensuring our platform generates libraries with a broad spectrum of antibodies, increasing the likelihood of finding candidates with the desired characteristics. Join us in advancing antibody research and development! 🧬 💻https://lnkd.in/gXJ9a6Bs #antibodyengineering #antibodies #antibodytherapeutics #antibodydiscovery #biotechnology #ranomics #NGS #yeastdisplay #researchanddevelopment #proteinengineering #dna
To view or add a comment, sign in
-
Check out our upcoming webinar and engage in a conversation about recombinant antibodies, antibody engineering and advanced antibody validation. Highly specific antibodies for Parkinson's disease focused on recombinant technologies "In our relentless pursuit of groundbreaking Parkinson's Disease research, precision is paramount. That's why we're thrilled to invite you to our upcoming virtual webinar: 'Highly specific antibodies for Parkinson's Disease focused on recombinant technologies' This webinar is your key to unlocking the precision of recombinant antibodies, raising the quality and impact of your Parkinson's research. Join us in pushing the boundaries of Parkinson's research and advancing the quest for improved treatments and a brighter future. Together, we can make a significant impact!" November 2nd - 1:00 PM EST & November 3rd - 11:00 AM CET Register now! https://lnkd.in/gDZeYacn #Recombinantantibodies #parkinsonsdisease #invitrogen #thermofisherantibodies #proteomics #antibodyvalidation #thermofisher #lifescience #antibodies
To view or add a comment, sign in
-
Antibody Basics: Hybridoma Sequencing 🧬 🧪 What is it? Hybridoma sequencing is the sequencing of the variable heavy (VH) and variable light (VL) domains of monoclonal antibodies produced from a hybridoma cell line. 💡 Why does it matter? Hybridoma technology revolutionized the field of antibody drug discovery by enabling the mass production of monoclonal antibodies to an antigen of interest. However, it has its limitations–contamination risks, low yield, and storage constraints. Hybridoma sequencing overcomes these challenges and prevents the loss of hybridoma cell lines. Biointron's hybridoma sequencing service offers fast turnaround times (1 week to deliver sequencing results after receiving the hybridoma cell line), and guaranteed 100% sequence accuracy (cross-verified with five independent clones). https://lnkd.in/ecs76rrh #Biointron #Antibodies #DrugDiscovery #Education #Hybridoma
Hybridoma Sequencing
biointron.com
To view or add a comment, sign in
757,580 followers
Innovative Leadership in Life Sciences & Technology Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies
1moExciting news, Genentech! The latest episode of "Two Scientists Walk Into A Bar" sounds fascinating. Antibody engineering is such a pivotal field in modern medicine, and I’m eager to hear Yan Wu and Paul Carter's insights on the advances in this area. The discussion on how #ArtificialIntelligence and #MachineLearning will revolutionize antibody design is particularly intriguing. Looking forward to listening! #AntibodyTherapies #AI #MachineLearning #BiotechInnovation